Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02534727 · ClinicalTrials.gov registry record
Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance
A clinical trial of Tuberculosis and Non-Tuberculosis Mycobacteria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 215
- Enrollment target
- 2
- Study locations
NCT02534727 is a study of Tuberculosis and Non-Tuberculosis Mycobacteria that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 215 participants, below the 927-participant average among 29 other Tuberculosis trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02534727, a study of Tuberculosis and Non-Tuberculosis Mycobacteria, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 215 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Many people around the world get tuberculosis (TB) and non-tuberculous mycobacteria (NTM) infections. Sometimes medicine that treats these infections does not get to where the bacteria are in the lungs. Researchers want to find a way to tell if enough medicine is getting to where it is needed in the lungs. They will look at how much medicine is in your sputum (what you cough up) compared to how much is in your blood. They will also investigate a new test to quickly figure out what medicines are likely to treat TB effectively. Objective: To determine the relationship between the concentration of TB drugs in plasma and sputum over time. Eligibility: People ages 18 and older who have TB or NTM infection that is suspected to be drug resistant. They must be taking TB or NTM medicines. Design: Participants will be screened with medical history. Participants will be in the study for 2 8 days. Participants will give 3 or more sputum samples over at least 2 different days. They will cough sputum into a cup. Participants will have blood drawn 4 times a day on 2 different days.
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Other
- Henan Provincial Chest Hospital - Zhengzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2016-01-27 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02534727
The ClinicalTrials.gov registry entry for NCT02534727 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 927-participant average among 29 other Tuberculosis trials with a reported enrollment target (77% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tuberculosis appearing as the primary indexed condition, and to 0 interventions.
NCT02534727 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT02534727 about?
NCT02534727 is a clinical study titled "Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance". Background: Many people around the world get tuberculosis (TB) and non-tuberculous mycobacteria (NTM) infections. Sometimes medicine that treats these infections does not get to where the bacteria are in the lungs. Researchers want to find a way to tell if enough medicine is getting to where it is ...
What is the current status of trial NCT02534727?
This trial is currently completed. The enrollment target is 215 participants. The study started on 2016-01-27. Estimated completion is 2020-12-31.
What conditions does trial NCT02534727 study?
This clinical trial studies the following conditions: Tuberculosis, Non-Tuberculosis Mycobacteria.
Who is sponsoring clinical trial NCT02534727?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02534727 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
RECRUITING
-
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
ACTIVE NOT RECRUITING
-
Gene Expression in HIV and Tuberculosis Co-infection
COMPLETED
-
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
COMPLETED · Phase 1
-
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.